Coronavirus mutations in New York, California spark concern

Mutations that have arisen in the US are spreading rapidly. Are they more contagious? And will the vaccines still be effective against them?

Since health authorities have begun sequencing positive COVID-19 cases more carefully — i.e., genetically examining test results — they have also found more and more mutations.

Most of those mutations are insignificant. But there are a few variants that researchers and officials are concerned about, in part because they are more contagious and because existing vaccines could be less effective at protecting against them.

In addition to the variants identified in Britain, South Africa, and Brazil, there are two more variants causing concern in the United States that appear to have evolved there.

In November, researchers first noticed a mutation in New York City called B.1.526. Since then, this variant has spread rapidly in the metropolis and across the state. By mid-February, it had been detected in 12% of all samples in New York that were gene sequenced.

This variant has also appeared in other countries such as Denmark.

The so-called California va

riant, first detected in July 2020, has also spread rapidly. Meanwhile, the two similar types, B.1.427 and B.1.429, of the California variant can be found in about a quarter of the gene-sequenced samples in California. ish mutant B.1.1.7, which has now been detected in a large number of countries, including Germany. The existing vaccines are thought to be somewhat less effective against the Californian virus variant, but still sufficient to protect patients from a severe course of COVID-19.

The New York virus variant, B.1.526, is similar to the South African variant, B.1.351, which has already been detected in more than 40 countries, and also shows similarity to the Brazilian variants, P.1 and P.2, which have been detected in more than 20 countries, most recently in the United Kingdom.

It is still unclear whether the New York variant is more contagious or dangerous, and whether existing vaccines are still sufficiently effective against this variant.

Finding the respective variants is only possible if you know what to look for. Although we now know the genome of SARSCoV-2, the virus is 29,903 nucleotides-long, which is far too long to make it possible to quickly identify which variants might make it more infectious among the 611,000 genomes now stored at the GISAID database.

The mutations were found using new software called Variant Database (VDB) developed at the California Institute of

Technology in Pasadena, by a team led by Pamela Bjorkman. It focuses on changes in the spike protein.

The potentially dangerous mutation E484K, which is present in B.1.351 and P.1, alters the receptor-binding domain of the spike protein, and this is where the antibodies with the strongest neutralizing effect attack.

The tip of the spike protein is also altered in the New York variant. Understandably, this has caused some worry, the epidemiologist Wafaa El-Sadr of Columbia University told the German public broadcaster, ARD. "These changes can result in the spike protein being able to attach itself better. Or that the virus can reproduce more quickly. Or that it cannot be fought by the antibodies through our vaccines," he said.

But, until detailed and robust data on the US variants is available, these observations remain speculative and there is no need to panic, said Dave Chokshi, commissioner at the New York City Department of Health and Mental Hygiene. As of yet, there isn't any evidence to show that it spreads faster, whether it's making people sicker or whether it reduces the effectiveness of the vaccine, he said.

This article has been translated from German.

No more freedom of movement. Some countries are trying to stem the spread of mutations by closing borders.